The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.
Paul James Wood
Research Funding - Novartis
Robyn Strong
Research Funding - Novartis
Grant A. McArthur
Consultant or Advisory Role - Amgen (U); Bristol-Myers Squibb (U); GlaxoSmithKline (U); Millennium (U); Novartis (U); Roche/Genentech (U)
Research Funding - Millennium; Novartis; Pfizer
Michael Michael
No relevant relationships to disclose
Elizabeth Algar
Honoraria - Novartis
Research Funding - Novartis
Andrea Muscat
Research Funding - Novartis
Lin Rigby
Research Funding - Novartis
David M. Ashley
Research Funding - Novartis